will not compensate foreign grantees for currency exchange fluctuations through the issuance of supplemental awards.

No funds appropriated under this Act shall be used to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

D. Where To Obtain Additional Information

This and other CDC announcements can be found on the CDC home page Internet address *http://www.cdc.gov/.* Click on "Funding" then "Grants and Cooperative Agreements."

If you have questions after reviewing the contents of all the documents, business management technical assistance may be obtained from: Cynthia Collins, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E–15, Atlanta, GA 30333. Telephone number: (770) 488–2757. E-Mail: coc9@cdc.gov.

For program technical assistance, contact: Karen Ryder, MPH, CDC/HIV, 2010 Abidjan Place, Dulles, VA 20189– 2010. Telephone: (404) 639–0911. E-Mail address: *kkr1@cdc.gov.*

Dated: October 9, 2002.

Edward J. Schultz,

Deputy Director, Procurement and Grants Office, Center for Disease Control and Prevention.

[FR Doc. 02–26526 Filed 10–17–02; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Interagency Committee on Smoking and Health Meeting: Correction

ACTION: Notice; Correction.

Name: Interagency Committee on Smoking and Health.

Date and Time: October 24, 2002, 8:30 a.m. to 2:15 p.m.

Correction

In the **Federal Register** of October 8, 2002, Volume 67, Number 195, Notices, Page 62727, under "PLACE" Should read: Hotel Monaco, 700 F Street, Athens Room, Washington, DC, (202) 628–7177.

Contact Person for More Information: Ms. Monica L. Swann, Committee Management Specialist, Interagency Committee on Smoking and Health, Office on Smoking and Health, NCCDPHP, CDC, 200 Independence Avenue, SW., Room 317B, Washington, DC, 20201, telephone (202) 205–8500.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: October 11, 2002.

Cynthia P. Johnson.

Acting Director, Management Analysis and Services Office Centers for Disease Control and Prevention.

[FR Doc. 02–26530 Filed 10–17–02; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N-0590]

Agency Information Collection Activities; Announcement of OMB Approval; Salmonella Discovery System Pilot Study

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Salmonella Discovery System Pilot Study" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (the PRA).

FOR FURTHER INFORMATION CONTACT: Karen L. Nelson, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: In the Federal Register of January 28, 2002 (67 FR 3902), the agency announced that the proposed information had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB Control Number 0910-0493. The approval expires on September 30, 2005. A copy of the supporting statement for this information collection is available on the Internet at http:// www.fda.gov/ohrms/dockets.

Dated: October 11, 2002. **Margaret M. Dotzel,** *Associate Commissioner for Policy.* [FR Doc. 02–26619 Filed 10–17–02; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 02N-0070]

Agency Information Collection Activities; Announcement of OMB Approval; Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring—Extension" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Karen L. Nelson, Office of Information Resources Management (HFA–250),

Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1482.

SUPPLEMENTARY INFORMATION: In the Federal Register of July 16, 2002 (67 FR 46679), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0409. The approval expires on September 30, 2005. A copy of the supporting statement for this information collection is available on the Internet at http:// www.fda.gov/ohrms/dockets.

Dated: October 11, 2002.

Margaret M. Dotzel,

Associate Commissioner for Policy. [FR Doc. 02–26620 Filed 10–17–02; 8:45 am] BILLING CODE 4160–01–8